Vyome Holdings (HIND) Net Cash Flow (2015 - 2026)
Vyome Holdings (HIND) posted quarterly Net Cash Flow of $3.9 million for Q1 2026, up 8950.54% year-over-year from $42571.0 in Q1 2025, and up 639.49% quarter-over-quarter from -$714178.0 in Q4 2025.
Vyome Holdings (HIND) Net Cash Flow (2015 - 2026) Analysis & Trends
Vyome Holdings' Net Cash Flow history runs 12 years deep, the most recent figure standing at $3.9 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 8950.54% year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at $8.8 million (up 321.23% YoY), while the FY2025 annual figure was $4.9 million, up 5731.6% from the prior year.
- Net Cash Flow for Q1 2026 stood at $3.9 million, up from -$714178.0 in the prior quarter.
- The five-year high for Net Cash Flow was $5.1 million in Q1 2023, with the low at -$7.4 million in Q1 2022.
- The 5-year median for Net Cash Flow is -$714178.0 (2025), against an average of -$701687.8.
- The sharpest annual moves came in 2025 and 2026: Net Cash Flow sank 1474.37% in 2025, then soared 8950.54% in 2026.
- Vyome Holdings' Net Cash Flow stood at -$2.3 million in 2022, then soared by 232.33% to $3.0 million in 2023, then slumped by 98.27% to $51964.0 in 2024, then tumbled by 1474.37% to -$714178.0 in 2025, then soared by 639.49% to $3.9 million in 2026.
- Business Quant data shows HIND's Net Cash Flow at $3.9 million in Q1 2026, -$714178.0 in Q4 2025, and $2.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.93 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.59 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.86 Bn | 53.73 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.42 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.19 Bn | 9.80 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 225.59 Mn |
| 10 | Vyome Holdings | 16.00 Mn | 8.11 Mn | 11,658.00 | -906,712.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -906,712.00 |
| Jun 30, 2026 | -906,712.00 |
| Mar 31, 2026 | 3.85 Mn |
| Mar 31, 2026 | 3.85 Mn |
| Dec 31, 2025 | -714,178.00 |
| Dec 31, 2025 | -714,178.00 |
| Sep 30, 2025 | 2.19 Mn |
| Sep 30, 2025 | 2.19 Mn |
| Jun 30, 2025 | 3.48 Mn |
| Jun 30, 2025 | 3.48 Mn |
| Mar 31, 2025 | -43,533.00 |
| Mar 31, 2025 | -43,533.00 |
| Dec 31, 2024 | 51,964.00 |
| Dec 31, 2024 | 51,964.00 |
| Sep 30, 2024 | 3.44 Mn |
| Sep 30, 2024 | 3.44 Mn |
| Jun 30, 2024 | -1.36 Mn |
| Jun 30, 2024 | -1.36 Mn |
| Mar 31, 2024 | -2.07 Mn |
| Mar 31, 2024 | -2.07 Mn |